- NCIt
- C8715
Loading cancer entity…
Loading cancer entity…
Clinical trials
12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 |
| clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | completed | Phase 2 | 291 | Children's Oncology GroupNETWORK | 5 | Jul 21, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jul 15, 2026source: clinicaltrials